Windlas Biotech Limited — PPTs, 05-02-2026: Investor Presentation

1. **Business Performance:**

Windlas Biotech hit its 12th consecutive record revenue quarter: Q3FY26 sales up 20% YoY to Rs 233 Cr. 9MFY26 revenue grew 19% YoY to Rs 666 Cr. Generic Formulations CDMO (+20% 9M, +23% Q3) and Exports (+29% 9M, +36% Q3) powered growth.

2. **Growth Drivers or Strategy:**

Company strategy: expand CDMO customer base, launch new products, boost international market penetration. Key drivers: strategic investments in Injectables and Plant-2 extensions, plus R&D in complex generics.

3. **Recent Developments:**

Q3FY26 saw record CDMO revenue: Rs 167 Cr. Injectables facility is GMP certified and contributing. Plant-6 for OSD capacity expansion is nearing mechanical completion by FY26 end.

4. **Key Financial Metrics:**

9MFY26 PAT: Rs 50 Cr (+13% YoY). EPS: Rs 24.02 (+12% YoY). Q3FY26 PAT reported Rs 15 Cr.

5. **Management Commentary / Outlook:**

Outlook: Leverage India's healthcare focus with affordable, high-quality medicines. Plans include strengthening capabilities, deepening customer ties, expanding products, and diversifying clients for long-term value.